<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03776695</url>
  </required_header>
  <id_info>
    <org_study_id>ZKT-002</org_study_id>
    <secondary_id>CTA1800062</secondary_id>
    <nct_id>NCT03776695</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients</brief_title>
  <official_title>Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tychan Pte Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Singapore Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke-NUS Graduate Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tychan Pte Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Zika virus (ZIKV) infection is a new emerging arbovirus disease, caused by the same vector&#xD;
      that transmits Dengue virus, Aedes aegypti. ZIKV is a growing public health problem, rapidly&#xD;
      spreading throughout the continents since the first epidemic was reported in the French&#xD;
      Polynesian islands.&#xD;
&#xD;
      Currently, there are several ZIKV vaccine candidates in clinical trials. However, no ZIKV&#xD;
      therapy (biologic or small molecule) has advanced to clinical trials. Tyzivumab will be the&#xD;
      first therapeutic in the world, specifically targeting ZIKV, to enter clinical trials.&#xD;
&#xD;
      This is a Phase 1, time-lagged, parallel-group, randomized, placebo-controlled, single-blind,&#xD;
      single ascending dose, Tyzivumab, ZIKV monoclonal antibody (mAb), study to be conducted in&#xD;
      ZIKV polymerase chain reaction (PCR) positive patients.&#xD;
&#xD;
      Tyzivumab will be administered once through single IV infusion over 30 minutes. Total&#xD;
      duration of study participation is estimated at approximately 85 days from the date of&#xD;
      screening. Post-trial monitoring through weekly telephone calls will continue from Day 85&#xD;
      post-dose onwards for another three (3) more months.&#xD;
&#xD;
      The main objective of this study is to evaluate the safety of Tyzivumab in acutely infected&#xD;
      adult patients. Assessment of time taken to achieve negative ZIKV isolation from acute ZIKV&#xD;
      infected subjects' blood will be the study's secondary objectives.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose escalation in this study will include 28 ZIKV-infected patients in four (4) dose&#xD;
      cohorts.&#xD;
&#xD;
      Eligible subjects will be enrolled into dose cohorts of seven (7) subjects each. Within each&#xD;
      dose cohort, subjects will be randomized to either Tyzivumab or Placebo Groups, with five (5)&#xD;
      subjects receiving Tyzivumab and two (2) receiving Placebo per cohort. There will be up to&#xD;
      four (4) dose levels / cohorts, for a total of 28 subjects. The proposed doses to be studied&#xD;
      are 2, 5, 10, and 20 mg/kg.&#xD;
&#xD;
      Within each dose cohort, a minimum of 48-hour interval is required between Tyzivumab dosing&#xD;
      of subject 1 and 2 and between subject 2 and 3, and a minimum of 24-hour interval is required&#xD;
      between Tyzivumab dosing of subject 3 and 4 and between subject 4 and 5. No such time&#xD;
      interval will be required for the Placebo dosing of subjects (i.e. a Placebo subject can be&#xD;
      dosed concurrently with or immediately after a Tyzivumab treatment subject). Dosing of the&#xD;
      last dose cohort (20 mg/kg) is optional if a trend of reduction in viral load and viral&#xD;
      isolation has been observed in dose level 1 (2 mg/kg), 2 (5 mg/kg) or 3 (10 mg/kg).&#xD;
&#xD;
      Dose escalations will be guided by review of clinical signs, adverse events (AEs), and&#xD;
      laboratory tests (including viral titre data) of the prior group (up to Day 7 after dosing)&#xD;
      by a safety monitoring committee. Safety analysis (up to Day 7) will also be completed for&#xD;
      the equivalent dose of ZKT-001 prior to the commencement of dosing in ZKT-002 for each&#xD;
      specified dose.&#xD;
&#xD;
      PD, PK and ADA measurements will be conducted at various time points throughout the study.&#xD;
      Subjects will be followed for up to approximately Day 84 safety and tolerability assessment.&#xD;
      Serum samples for PD, PK and ADA assessments, and urine samples for PD assessments will be&#xD;
      taken at specified time points.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Event (Safety and Tolerability)</measure>
    <time_frame>84 Days</time_frame>
    <description>Presence or absence of infusion reaction (hypersensitivity / anaphylaxis / etc.) in dose cohorts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral Clearance Post-Tyzivumab Infusion (Efficacy)</measure>
    <time_frame>84 Days</time_frame>
    <description>Time taken to achieve ZIKV clearance (CL) from blood via negative virus isolation in subjects acutely infected with ZIKV when given an IV infusion of Tyzivumab</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Treatment of Acute Zika Virus Infection</condition>
  <arm_group>
    <arm_group_label>2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered with 2 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg/kg - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered with 5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg/kg - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered with 10 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg/kg - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered with 20 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg/kg - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tyzivumab</intervention_name>
    <description>Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb)</description>
    <arm_group_label>10 mg/kg</arm_group_label>
    <arm_group_label>2 mg/kg</arm_group_label>
    <arm_group_label>20 mg/kg</arm_group_label>
    <arm_group_label>5 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Saline</description>
    <arm_group_label>10 mg/kg - Placebo</arm_group_label>
    <arm_group_label>2 mg/kg - Placebo</arm_group_label>
    <arm_group_label>20 mg/kg - Placebo</arm_group_label>
    <arm_group_label>5 mg/kg - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult volunteers, aged 21 to 60, men or women&#xD;
&#xD;
             a. Women must fulfil one (1) of the following criteria: i. Post-menopausal; either&#xD;
             amenorrhea ≥ 12 months or follicle stimulating hormone &gt; 40 mIU/mL ii. Surgically&#xD;
             sterile; hysterectomy, bilateral oophorectomy, or tubal ligation iii. Women of&#xD;
             childbearing potential participating in heterosexual sexual relations must be willing&#xD;
             to use adequate contraception from screening day until 100 days post-infusion b. Male&#xD;
             subjects who are non-vasectomized (or vasectomized less than six (6) months prior to&#xD;
             dosing) and have female partners of childbearing potential must be willing to use an&#xD;
             effective birth control method when having heterosexual intercourse, from screening&#xD;
             day until 100 days post-infusion&#xD;
&#xD;
          2. Any one or a combination of symptoms and signs suggestive of ZIKV acute infection,&#xD;
             presenting within 48 hours from onset&#xD;
&#xD;
          3. Positive ZIKV PCR for acute ZIKV infection&#xD;
&#xD;
          4. Subjects who are willing to comply with the requirements of the study protocol and&#xD;
             attend scheduled visit&#xD;
&#xD;
          5. Subjects who give written informed consent approved by the Ethical Review Board&#xD;
             governing the site&#xD;
&#xD;
          6. Satisfactory baseline medical assessment as assessed by physical examination and&#xD;
             normal laboratory values or minor variations that are acceptable for study entry&#xD;
&#xD;
          7. Accessible vein in the forearm for blood collection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,&#xD;
             neuropsychiatric, or immunosuppressive disorders&#xD;
&#xD;
          2. Evidence of clinically significant anaemia (HB &lt; 10 g/dL) or any other significant&#xD;
             active haematological disease, or having donated &gt; 450 mL of blood within the past&#xD;
             three (3) months&#xD;
&#xD;
          3. Evidence of substance abuse, or previous substance abuse&#xD;
&#xD;
          4. Participation or planned participation in a study involving the administration of an&#xD;
             investigational compound within the past four (4) months or during this study period&#xD;
&#xD;
          5. Planned administration of any vaccine not foreseen by the study protocol 12 weeks&#xD;
             before first dosing day and up to four (4) months after dosing&#xD;
&#xD;
          6. Receipt of immunoglobulins and/or any blood products within nine (9) months of study&#xD;
             enrolment or planned administration of any of these products during the study period&#xD;
&#xD;
          7. History of any reaction to monoclonal antibodies&#xD;
&#xD;
          8. Pregnant or lactating women, or women of childbearing potential who are unwilling to&#xD;
             use adequate contraception&#xD;
&#xD;
          9. Any condition that, in the opinion of the investigator, would complicate or compromise&#xD;
             the study or well-being of the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenny Low, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justin Ng, PhD</last_name>
    <phone>+6590025606</phone>
    <email>justin@tychanltd.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SingHealth Investigational Medicine Unit</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Hong Tay</last_name>
      <phone>+65 6323 7532</phone>
      <email>tay.bo.hong@singhealth.com.sg</email>
    </contact>
    <contact_backup>
      <last_name>Robyn Yip</last_name>
      <phone>+65 6323 7552</phone>
      <email>robyn.yip.y.p@singhealth.com.sg</email>
    </contact_backup>
    <investigator>
      <last_name>Jenny Low, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 12, 2018</study_first_submitted>
  <study_first_submitted_qc>December 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2018</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zika Virus Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

